Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: May 2011
-
The Biotechnology Industry Organization (BIO) will be holding its annual BIO International Convention on June 27-30, 2011 in Washington, DC. Founded in 1993, BIO is a nonprofit association seeking supportive biotechnology policies on behalf of more than 1,100 biotechnology companies, state and international affiliates, and related organizations, as well as providing business development services for…
-
American Conference Institute (ACI) will be holding the West Coast Edition of its Advanced Forum on Life Sciences Collaborative Agreements and Acquisitions from July 20-21, 2011 in San Francisco, CA. The conference will allow attendees to: • Position their companies in light of emerging trends in deal structuring and increasing M&A activity;• Optimize business development…
-
By Kevin E. Noonan — The Federal Circuit continued its explication both of the contours of obviousness for pharmaceutical formulations after KSR Int'l Co. v. Teleflex Inc. as well as how it exercises its supervisory powers over the U.S. Patent and Trademark Office after Dickinson v. Zurko, in a decision last Friday, In re Huai-Hunk…
-
By Donald Zuhn — Last week, in Ex parte DeGrado, an appeal before the Board of Patent Appeals and Interferences concerning U.S. Application No. 10/801,951 (U.S. Patent Application Publication No. US 2006/0041023), the Board issued an order calling for further briefing on two issues related to a claim that the Board "conservatively estimate[s] . . .…
-
By Kevin E. Noonan — The Supreme Court refused today to grant certiorari in Eli Lilly & Co. v. Sun Pharmaceutical Industries, Ltd. on the question of obviousness-type double patenting. In doing so, the Court let stand precedent that seriously expands the scope of the obviousness-type double patenting standard, turning a legal principle that was…
-
By Donald Zuhn — The U.S. Patent and Trademark Office announced today that it is expanding the Enhanced First Action Interview pilot program to include all utility applications in all technology areas and filing dates. Like its predecessor programs, under the Full First Action Interview pilot program, an applicant is entitled to a first action…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Elan Corp. et al. v. Teva Pharmaceuticals USA Inc.1:11-cv-00367; filed April 25, 2011 in the District Court of Delaware • Plaintiffs: Elan Corp. plc; Elan Pharma International Ltd.• Defendant: Teva Pharmaceuticals USA Inc. Infringement of…
-
May 18-19, 2011 – Forum on Freedom to Operate (C5) – Munich, Germany May 23-25, 2011 – 6th International Judges Conference on Intellectual Property Law (Intellectual Property Owners Association) – Brussels, Belgium June 2, 2011 – EPO Opposition & Appeals — The Case Law (Patent Resources Group and Management Forum) – Chicago, IL June 3,…
-
American Conference Institute (ACI) will be holding the next session of its Hatch-Waxman Boot Camp conference on July 18-19, 2011 in San Diego, CA. ACI faculty will help attendees: • Understand the interplay of the PTO and FDA in the patenting of drugs and biologics;• Learn about the essentials of the FDA approval process and…
-
By Donald Zuhn — A study released earlier this year by Ocean Tomo highlights the emergence of intellectual capital and how the U.S. has transitioned to an innovation-based economy over the past 35 years. The company's Intangible Asset Market Value study indicated that in 2010, 80% of company value (for the S&P 500) was comprised…
Patent Docs 